Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor patents



      
           
This page is updated frequently with new Factor-related patent applications. Subscribe to the Factor RSS feed to automatically get the update: related Factor RSS feeds. RSS updates for this page: Factor RSS RSS



Date/App# patent app List of recent Factor-related patents
07/30/15
20150215560 
 Image sensor for endoscopic use patent thumbnailnew patent Image sensor for endoscopic use
An endoscopic device having embodiments of a hybrid imaging sensor that optimizes a pixel array area on a substrate using a stacking scheme for placement of related circuitry with minimal vertical interconnects between stacked substrates and associated features are disclosed. Embodiments of maximized pixel array size/die size (area optimization) are disclosed, and an optimized imaging sensor providing improved image quality, improved functionality, and improved form factors for specific applications common to the industry of digital imaging are also disclosed.
Olive Medical Corporation


07/30/15
20150213220 
 Monitoring patient health patent thumbnailnew patent Monitoring patient health
A system and associated methods are provided monitoring patient health. A composite risk score is computed based upon the relevance of a set of risk factors to a patient.
Prevail Holdings Inc.


07/30/15
20150211041 
 Programmable nor-based device for transcription profile analyses patent thumbnailnew patent Programmable nor-based device for transcription profile analyses
An autonomous synthetic programmable device adapted to determine a cell state according to one or more different predefined markers, comprising a transcription machinery and a regulatory element for regulating said transcription machinery, said regulatory element comprising at least three different binding regions, each binding region binding a different transcription factor and each binding region corresponding to a different predefined marker, wherein the regulatory element permits said transcription machinery to provide a transcription output if and only if all three different transcription factors are absent and wherein each transcription factor is capable of blocking transcription by said transcription machinery and hence blocking said transcription output.. .
Yeda Research And Development Co., Ltd.


07/30/15
20150210994 
 Fvii polypeptide variants exhibiting altered interaction with endothelial protein c receptor (epcr) and methods of use thereof for modulating hemostasis patent thumbnailnew patent Fvii polypeptide variants exhibiting altered interaction with endothelial protein c receptor (epcr) and methods of use thereof for modulating hemostasis
factor vii variants and methods of use thereof are disclosed.. .
The Children's Hospital Of Philadelphia


07/30/15
20150210771 
 Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies patent thumbnailnew patent Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.. .

07/30/15
20150210760 
 Therapeutic  pancreatic cancer patent thumbnailnew patent Therapeutic pancreatic cancer
The present invention relates to methods and medicarnents useful for treating locally advanced pancreatic cancer (lapc). Improved therapeutic methods and regimens comprising anti-connective tissue growth factor (ctgf) agents, including anti-ctgf antibodies, are provided.
Fibrogen, Inc.


07/30/15
20150210737 
 Integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma patent thumbnailnew patent Integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma
The purification carried out by an all-chromatography scheme, avoids the use of ethanol precipitation in the entire manufacturing process of the said four plasma products. The invention describes an integrated process for purifying four different proteins from human plasma to high therapeutic grade purity levels, with a potential to purify more therapeutic proteins from a given plasma sample by incorporating additional chromatography steps in the sequence..

07/30/15
20150210694 
 Inhibitors of the fibroblast growth factor receptor patent thumbnailnew patent Inhibitors of the fibroblast growth factor receptor
Described herein are inhibitors of fgfr, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.. .
Blueprint Medicines Corporation


07/30/15
20150210691 
 Lactam-containing compounds and derivatives thereof as factor xa inhibitors patent thumbnailnew patent Lactam-containing compounds and derivatives thereof as factor xa inhibitors
Or pharmaceutically acceptable salt forms thereof, wherein ring p, if present is a 5-7 membered carbocycle or heterocycle and ring m is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor xa..

07/30/15
20150209426 
 Treatment of cancer patent thumbnailnew patent Treatment of cancer
A method for treating breast cancer with an insulin-like growth factor (igf) receptor antagonist in combination with exemestane and everolimus.. .
Boehringer Ingelheim International Gmbh


07/30/15
20150209417 
new patent

Single-dose administration of factor viia


The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a factor viia equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg factor viia equivalent..
Novo Nordisk Healthcare Ag


07/30/15
20150209389 
new patent

Methods of generating mesenchymal stem cells which secrete neurotrophic factors


A method of generating mscs which secrete neurotrophic factors (ntfs) comprising incubating a population of undifferentiated mesenchymal stem cells (mscs) in a differentiating medium comprising basic fibroblast growth factor (bfgf), platelet derived growth factor (pdgf), heregulin and camp.. .
Brainstorm Cell Therapeutics Ltd.


07/30/15
20150209324 
new patent

Use of flavone compound for prevention or treatment of obesity


The present invention relates to a pharmaceutical composition containing flavone compound as an active ingredient for treating obesity, and more specifically to a pharmaceutical composition for preventing or treating obesity and a dietary composition for preventing or reducing obesity containing 5,7-dimethoxyflavone or 5,7,4′-trimethoxyflavone. The compound according to the present invention inhibits adipogenesis, and reduces expression of the key transcription factors (srebp1c and c/ebp) related to lipogenesis and of enzyme proteins (fas and acc) related to adipogenesis, and thus is effective in preventing or treating obesity..
Industry-academic Cooperation Foundation, Yonsei University


07/30/15
20150209005 
new patent

Ultrasound endoscope and methods of manufacture thereof


To address limitations of conventional transducers, a phased array transducer is provided with a form factor suitable o for packaging into, e.g., an endoscope. A method of manufacture of small packaging transducers is also provided, whereby the overall package size is reduced by electrically connecting signal wires to array electrodes at an angle approximately normal to the array surface, thus largely eliminating the bend radius requirements of conventional printed circuit boards or flex circuits..
Dalhousie University


07/30/15
20150208963 
new patent

Micro sensing system for detecting neurotrophic factors


A micro sensing system for real-time sensing a neurotrophic factor included in a body fluid includes a body, a neurotrophic factor channel formed in the body to allow a fluid flow therein, and a biosensor formed at the body to sense the neurotrophic factor, wherein the body fluid is extracted in a living body through the neurotrophic factor channel, and wherein the biosensor is disposed on a path of the neurotrophic factor channel to directly contact a body fluid flowing through the neurotrophic factor channel and senses a concentration of a neurotrophic factor in the body fluid.. .
Korea Institute Of Science And Technology


07/23/15
20150204892 

Methods and compositions for diagnosis and prognosis of renal injury and renal failure


The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of tumor necrosis factor receptor superfamily member 10b, cadherin-16, caspase-9, bcl2 antagonist of cell death, caspase-1, cadherin-1, poly [adp-ribose] polymerase 1, cyclin-dependent kinase inhibitor 1, cadherin-5, myoglobin, apolipoprotein a-ii, mucin-16, carcinoembryonic antigen-related cell adhesion molecule 5, and cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries..
Astute Medical, Inc.


07/23/15
20150204887 

Human myeloid derived suppressor cell cancer markers


Provided herein are methods for determining the presence of cancer (malignant versus benign), monitoring the progression of cancer, monitoring cancer relapse, monitoring the response to cancer therapy, or cancer staging in a subject, by evaluating cd33+/hla-drlow, cd14+/hla-drlow, cd66b+/hla-drlow or, cd11b+/hla-drlow mdsc for activation of a transcription factor. Transcription factors include, but are not limited to, stat3, pstat3, hif1α, or c/ebpβ.
University Of Southern California


07/23/15
20150204537 

Boiler system


The invention improves system efficiency with no waste of heat held by a stopped boiler. A boiler system includes a boiler group having a plurality of boilers and a controller for controlling a combustion state of the boiler group.
Miura Co., Ltd.


07/23/15
20150203859 

Nucleic acid sequences encoding transcription factors regulating alkaloid biosynthesis and their use in modifying plant metabolism


Plant metabolism and alkaloid levels can be regulated by transcription factors that regulate the nicotinic alkaloid biosynthetic pathway. In one embodiment, the disclosure provides a transcription factor that negatively regulates alkaloid biosynthesis, such as nicotine biosynthesis..
22nd Century Limited, Llc


07/23/15
20150203821 

Immortalized stem cell, compositions, preparations and uses thereof


The purpose of the present invention is to provide immortalized stem cells, which produce a growth factor capable of regenerating various kinds of tissues that have been damaged by a variety of causes, and a method for producing the aforesaid immortalized stem cells. Another purpose of the present invention is to provide a medicinal composition and a medicinal preparation for restoring damaged tissues, and a method for the percutaneous absorption of a culture supernatant.
Quarrymen Corporation


07/23/15
20150203585 

Use of dr6 and p75 antagonists to promote survival of cells of the nervous system


The present invention relates to death receptor-6 (dr6) proteins which are members of the tumor necrosis factor (tnf) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for dr6.
Biogen Idec Ma Inc.


07/23/15
20150203566 

Fgfr1 extracellular domain combination therapies


Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (fgfr1) extracellular domain (ecd) and/or an fgfr1 ecd fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-fu), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an fgfr1 ecd and/or an fgfr1 ecd fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-fu), leucovorin, pemetrexed, and bevacizumab are also provided.
Five Prime Therapeutics, Inc.


07/23/15
20150203497 

Composition, synthesis, and use of new substituted pyran and pterin compounds


The present invention relates to substituted pterin compounds, their synthesis and use. In particular, the present invention relates to a new precursor compound and its analogs for synthesizing a new substituted pterin compound and its analogs.
Duquesne University Of The Holy Ghost


07/23/15
20150203492 

Dihydropyridone p1 as factor xia inhibitors


The present invention provides compounds of formula (x): (formula (x), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor xia inhibitors or dual inhibitors of fxia and plasma kallikrein.
Bristol-myers Squibb Company


07/23/15
20150202265 

Method for preparing a bone protein preparation and a bone protein preparation


The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation..
Bbs-bioactive Bone Substitutes Oy


07/23/15
20150202264 

Platelet activation and growth factor release using electric pulses


Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample.
General Electric Company


07/23/15
20150201694 

Stretchable, flexible electronic patch for monitoring impacts and other events


This invention comprises a stretchable electronic patch for monitoring impacts and other events. The stretchable, flexible electronic impact monitor patch includes geometric patterning of the substrate which enables stretching and flexing of the patch while leaving substrate regions at low strain for placement of electronic components, sensors and interconnects, maintaining electrical function during stretching and flexing.

07/16/15
20150199782 

Population health risk stratification using multi-dimensional model


Various disclosed embodiments include methods and systems for population health risk stratification. The population comprises a plurality of patients.
Psc, Inc.


07/16/15
20150199762 

Methods and computer software applications for selecting securities for an investment portfolio


Provided are methods and computer software applications for generating a stock portfolio, and/or enhanced stock index, through using a plurality of growth factors and a plurality of value factors to rank stocks, and for constructing investment vehicles based on the stock portfolio. The method, software application, or computer apparatus of the present technology employs a novel stock selection strategy to select stocks from a pre-selected universe of securities such as a commercially available stock market index in order to create a stock portfolio, and/or enhanced stock index, and a fund based thereon that can generate positive alpha as compared to a fund based on the pre-selected universe of securities..
First Trust Portfolios L.p.


07/16/15
20150197814 

Egfr and kras mutations


The present invention relates to mutations in epidermal growth factor receptor (egfr) and kras and methods of detecting such mutations as well as prognostic methods for identifying tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated egfr gene or mutated egfr protein and/or a mutated kras gene or mutated kras protein in a tumor sample..
Genentech, Inc.


07/16/15
20150197768 

Plant transcription factors, promoters and uses thereof


Polynucleotide molecules encoding transcription factors, promoter elements, binding partners and methods of use in increasing drought tolerance, yield, and abiotic stress tolerance are disclosed. Erf transcription factors and cor410b promoter sequences are disclosed..
Pioneer Hi Bred International Inc.


07/16/15
20150197730 

Oncolytic virus therapy for resistant tumors


Disclosed herein is a recombinant oncolytic virus comprising a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (trail). One such oncolytic virus is ohsv.
The General Hospital Corporation


07/16/15
20150197564 

Anti-angptl3 antibodies and uses thereof


A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hangptl3) is provided. The human anti-hangptl3 antibodies are useful in treating diseases or disorders associated with angptl3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth.
Regeneron Pharmaceuticals, Inc.


07/16/15
20150197552 

Compositions and methods of treatment of black hemophiliac patients


It has been determined that most mutations in factor viii occur in multiple haplotypes, not primarily in one haplotype. The frequencies of mild, moderate, and severe hemophilia did not differ significantly according to the background haplotype.
Haplomics, Inc.


07/16/15
20150197519 

Inhibitors of the fibroblast growth factor receptor


Described herein are inhibitors of fgfr-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of fgfr-4.. .
Blueprint Medicines Corporation


07/16/15
20150196656 

Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof


Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (igf-1) and variants thereof, epidermal growth factor (egf), and other ligands to the egf receptor, are provided. The fusion proteins further comprise seq id no:1 or other segments having lysine, glutamic acid, or aspartic acid residues.

07/16/15
20150196652 

Nucleic acid complexes


The present invention relates to complexes of transcription factor decoys, their delivery to bacteria and their formulation. In particular, the present invention resides in an antibacterial complex comprising a nucleic acid sequence and one or more delivery moieties selected from quaternary amine compounds; bis-aminoalkanes and unsaturated derivatives thereof, wherein the amino component of the aminoalkane is an amino group forming part of a heterocyclic ring; and an antibacterial peptide..
Procarta Biosystems Ltd


07/16/15
20150196620 

System and multiphasic release of growth factors


A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile releases at least one growth factor over a period of hours to days, wherein the growth factor is released in a large amount initially, with the remainder being released in progressively lower amounts.
Induce Biologics, Inc.


07/16/15
20150196602 

Stem cell therapy for crohn's disease and ulcerative colitis


A therapeutic process for treating an inflammatory bowel disease (ibd) using mesenchymal stem cells includes the steps of isolating a plurality of human mesenchymal stem cells from a human patient, introducing the plurality of human mesenchymal stem cells into the human patient, reducing human pro-inflammatory cytokines, wherein the human pro-inflammatory cytokines include il-12 and il-18, and increasing human anti-inflammatory cytokines, wherein the human anti-inflammatory cytokines include il-10 and tgf-beta. The human mesenchymal stem cells are isolated from an umbilical cord blood or from a human adipose tissue.

07/16/15
20150196371 

Endosseous dental implant assembly


An endosseous dental implant assembly comprises a dental implant comprising an abutment portion for connecting to a tooth crown and a hollow base portion defining a cavity therein, and a bio-supportive or biodegradable scaffold carried by the hollow base portion of the dental implant in the biomimetic approach. The abutment portion is formed integrally with the hollow base portion.

07/16/15
20150196209 

Cardiovascular risk factor sensing device


Various technologies described herein pertain to sensing cardiovascular risk factors of a user. A chair includes one or more sensors configured to output signals indicative of conditions at site(s) on a body of a user.
Microsoft Corporation


07/16/15
20150196017 

Compositions and methods of treatment of black hemophiliac patients


It has been determined that most mutations in factor viii occur in multiple haplotypes, not primarily in one haplotype. The frequencies of mild, moderate, and severe hemophilia did not differ significantly according to the background haplotype.
Haplomics, Inc.


07/09/15
20150194939 

Means for dynamic electronic or digital programmable control of analog high or low voltage audio signals in music instrument amplifiers


A method for providing digital or electronic control, using electrical isolation or optical decoupling devices, of an analog music instrument amplifier, whether vacuum tube or transistor based, that allows real-time or digitally programmable control over the analog circuitry of said music instrument amplifiers, without altering the currently available form factors or audio qualities of said amplifiers is provided.. .

07/09/15
20150194932 

Method and system for crest factor reduction


Methods and systems for crest factor reduction may comprise generating an original waveform, generating a distortion signal by reducing a crest factor of the original waveform, generating an error signal by subtracting out the original waveform from the distortion signal, generating a conditioned waveform by adding the error signal to the original waveform, and amplifying the conditioned waveform. The crest factor of the original waveform may be reduced based on spectral mask requirements.
Maxlinear, Inc.


07/09/15
20150194369 

Semiconductor package with conductive clips


One exemplary disclosed embodiment comprises a high power semiconductor package configured as a buck converter having a control transistor and a sync transistor disposed on a common leadframe pad, a driver integrated circuit (ic) for driving the control and sync transistors, and conductive clips electrically coupling the top surfaces of the transistors to substrate pads such as leadframe pads. In this manner, the leadfirame and the conductive clips provide efficient grounding or current conduction by direct mechanical connection and large surface area conduction, thereby enabling a package with significantly reduced electrical resistance, form factor, complexity, and cost when compared to conventional packaging methods using wirebonds for transistor interconnections..
International Rectifier Corporation


07/09/15
20150193777 

System and using flexible circuitry in payment accessories


Systems and methods described herein may comprise rfid data acquisition technology which may be embedded in a fob or tag for use in completing financial transactions. This fob may a self-contained device which includes a transponder and which may be contained on any portable form factor and may comprise flexible circuitry.
American Express Travel Related Services Company, Inc.


07/09/15
20150193583 

Decision support from disparate clinical sources


Systems, methods and computer-readable media are provided for facilitating clinical decision support and managing patient population health by health-related entities including caregivers, health care administrators, insurance providers, and patients. Embodiments of the invention provide decision support services including providing timely contextual patient information including condition risks, risk factors and relevant clinical information that are dynamically updatable; imputing missing patient information; dynamically generating assessments for obtaining additional patient information based on context; data-mining and information discovery services including discovering new knowledge; identifying or evaluating treatments or sequences of patient care actions and behaviors, and providing recommendations based on this; intelligent, adaptive decision support services including identifying critical junctures in patient care processes, such as points in time that warrant close attention by caregivers; near-real time querying across diverse health records data sources, which may use diverse clinical nomenclatures and ontologies; improved natural language processing services; and other decision support services..
Cerner Innovation, Inc.


07/09/15
20150193372 

Method and plug and play, networkable iso 18000-7 connectivity


A device may comprise a universal serial bus (usb) interface and a wireless interface operable to communicate in accordance with the iso 18000-7 standard. The device may be operable to receive a command via the usb interface and transmit the command via the wireless interface.
Blackbird Technology Holdings, Inc.


07/09/15
20150192693 

Quantum dot-based identification, location and marking


An identification system includes a quantum dot form factor disposed on an article, and quantum dots disposed on the quantum dot form factor, the quantum dots emitting a predetermined emission. A marking system includes a secondary reservoir including a plurality of quantum dots configured to be expelled from the reservoir and a means for dispersing the quantum dots from the secondary reservoir to engage the area to be marked.
Raytheon Company


07/09/15
20150192594 

Fibroblast growth factor receptors as diagnostic markers of acquired sensory neuronopathies


The present invention relates to the diagnosis of acquired sensory neuronopathies (snn), and to the treatment of these disorders.. .
Centre Hospitalier Universitaire De Saint Etienne


07/09/15
20150191535 

Bispecific, bivalent anti-vegf/anti-ang2 antibodies


The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (vegf/vegf-a) and against human angiopoietin-2 (ang-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. .
Hoffmann-la Roche Inc.


07/09/15
20150191526 

Cell line expressing single chain factor viii polypeptides and uses thereof


The present invention provides cell lines for producing single chain fviii polypeptides, e.g., chimeric single chain fviii polypeptides, methods of producing single chain fviii polypeptides, single chain fviii polypeptides, and methods of treating hemophilia a with a single chain factor viii polypeptide.. .
Biogen Idec Ma Inc.


07/09/15
20150191521 

Dominant negative transcription factor for antagonizing oncogenic transcription factors via multimerization


The present invention teaches compositions, methods and kits for treating or preventing cancer in a subject by using a dominant negative transcription factor and/or a multimerization adaptor. The invention teaches that the dominant negative transcription factor can antagonize an oncogenic transcription activator and can cause cell cycle arrest and cell death in a cancer cell.
Cedars-sinal Medical Center


07/09/15
20150191515 

Compositions and methods for modulating biomass productivity


The disclosure generally relates to methods and materials for modulating cell productivity. In particular, the present disclosure provides polynucleotides encoding transcription factor proteins that when overexpressed in microrganisms result in increased in productivity, such as increased biomass productivity.
Synthetic Genomics, Inc.


07/09/15
20150191417 

Anti-proliferative compounds and uses thereof


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject.
The General Hospital Corporation D/b/a Massachusetts General Hospital


07/09/15
20150190969 

Bone regeneration material


A method of manufacturing a bone substitute structure for reconstruction of bone material in a patient. The method comprises the steps of providing data reflecting a cavity in a bone of a patient, defining and modelling a three dimensional structure corresponding to the cavity in the bone; and providing an individualized bone substitute structure, corresponding to the defined and modeled three dimensional structure, by combining calcium phosphate cement, growth factors and the patient's own un-coagulated blood..
Nobel Biocare Services Ag


07/09/15
20150190478 

New protecting compositions for recombinantly produced factor vii


A histidine-free composition comprising: a high purity factor viii (r-factor viii); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor viii; an amount of calcium chloride for specific stabilization of factor viii.. .
Octapharma Ag


07/02/15
20150188270 

Slide battery and power tool for use with both slide and post batteries


Batteries having different form factors and power tools that are capable of using such batteries are described. In some embodiments, a power tool may use batteries having a post form factor as well as batteries having a slide form factor..
Sears Brands, Llc


07/02/15
20150187014 

System and expectation based processing


A system for determining insurance pricing information based on telematics data, the system comprising, a processor configured to generate a driver proxy score (dps) based on a combination of rating variables in a conventional class plan; the processor, configured to receive information associated with telematics data received from a telematics device, wherein the telematics data includes a plurality of risk factors; the processor further configured to determine a driver telematics score (dts) based on the information associated with the telematics data; the processor further configured to generate an expectation based rating, based on the dps and the dts, which measures a variance of the telematics data from the expected value; the processor further configured to update pricing information based on the determined expectation based rating; and a transmitter configured to transmit the updated pricing information to a user device.. .
Hartford Fire Insurance Company


07/02/15
20150186818 

Portfolio analysis enhancement to entity mobility/productivity opportunities


Systems and methods are disclosed for assessing a relocation option. More specifically, a line of business may assess a relocation option by generating a geographic model that may be based on data about a relocation option.
Bank Of America Corporation


07/02/15
20150186814 

Supplier technical oversight risk assessment


A system is provided that may receive assignment of quantitative risk ratings to respective characteristic elements and respective technical-profile elements based on applicability of the respective characteristic elements to a particular product and a particular manufacturing supplier. And the system may generate a technical risk assessment of the particular manufacturing supplier for the particular product, with the technical risk assessment including a plurality of risk factors each of which may be related to one or more characteristic elements and technical-profile elements.
The Boeing Company


07/02/15
20150186320 

Backward compatible new form factor connector


A computing system can include an electronic device including a controller and a new form factor (nff) receptacle. The computing system can also include a legacy-compatible adapter coupled to the nff receptacle to couple the electronic device to a second electronic device.

07/02/15
20150185230 

Identification of patients with abnormal fractional shortening


The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac troponin and/or fibroblast growth factor 23 (fgf-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts).
Roche Diagnostics Operations, Inc


07/02/15
20150185214 

Methods and kits for measuring von willebrand factor


Methods and kits for measuring levels of von willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein ibα having a combination of g233v, d235y and m239v mutations and an agent to detect a complex between the recombinant glycoprotein ibα and von willebrand factor.. .
The Medical College Of Wisconsin, Inc.




Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.0525

5045

0 - 1 - 101